Henry Schein, Inc.
Rank #165Capital ReturnHSIC · Nasdaq · Healthcare
Henry Schein, Inc. (HSIC) — Rank #165 by gross profitability (GP/assets 0.36) · ROE 12.6% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001000228 · all metrics point-in-time as of the filing date.
About
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Show moreShow less
It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc.
was founded in 1932 and is headquartered in Melville, New York.
- Industry
- Medical Distribution
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 26
- Website
- henryschein.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$10.04B
P/E (annual)
27.0
P/S (annual)
0.8
P/B
3.2
P/OCF (annual)
14.1
Shareholder Yield
23.1%
Employees
25,000
Industry
Medical Distribution
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholdsWhat Growth Is Priced In
Implied revenue growth (10Y)
6.8%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -23.1% — per-share value needs a total required return of -16.2% once share-count change is priced in.
vs. own 6-year median revenue growth: 3.7%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
2.6%
r = 10% (base)
6.8%
r = 12%
10.5%
Net debt / market cap: 8.1%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Disclosure regression check
A previously-disclosed line item is no longer reported. Worth checking the filing for why.
FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.36
Primary signal (Novy-Marx).
6th of 9 SIC 50 peers
Return on equity
12.6%
Gross margin
31.1%
5th of 9 SIC 50 peers
Revenue growth (YoY)
5.8%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2018 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
1.4%
Revenue CAGR (5Y)
5.4%
Earnings CAGR (3Y)
-9.6%
FCF CAGR (3Y)
4.2%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.74
9th of 9 SIC 50 peers (best = lowest)
Current ratio
1.32×
9th of 9 SIC 50 peers
Quick ratio
0.55×
Net cash
-$867.00M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$573.00M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.44
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
0.3%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.